Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to determine if the Quest AD-Detect blood test can help diagnose underlying Alzheimers disease earlier in patients hospitalized with cognitive issues such as delirium or encephalopathy. The study focuses on patients aged 60 to 90 who have no prior diagnosis of dementia but show cognitive impairment possibly related to toxic or metabolic conditions. Researchers want to see if the blood test can distinguish Alzheimers disease from other causes of cognitive problems in the hospital setting. All eligible patients will have their blood collected and tested using the Quest AD-Detect blood test during their hospital stay. The study involves only one group where every participant receives this diagnostic blood test. There are no placebo or comparison groups in this trial. Participants will be followed up for six months after hospitalization through a Neurology Clinic to discuss their risk assessment results. The main outcome measured is the percentage of patients with a positive biomarker for Alzheimers dementia among those presenting with cognitive diagnoses. The trials total duration extends from enrollment to the six-month post-hospital follow-up visit.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether a modified version of metaxalone 640 mg can reduce pain in adults experiencing acute low back and leg pain associated with lumbar spinal stenosis and sciatica. This phase 4, double-blind, randomized, placebo-controlled trial compares the effects of metaxalone plus standard care to a placebo in patients aged 18 to 80 years who are otherwise healthy and have newly occurring pain. Participants will be randomly assigned to one of two groups one receiving metaxalone 640 mg oral tablets every 6 hours for 7 days, and the other receiving an inactive placebo capsule on the same schedule. The study is conducted across multiple centers with a parallel design and includes a pilot phase followed by a larger randomized study. During the trial, participants will complete surveys on Day 1 before treatment and again on Day 7 to report on pain intensity, the impact of pain on physical activity, and sleep interference. The primary outcome measure is the change in the Numeric Pain Scale score from Day 1 to Day 7. Participants will be monitored for adherence and safety throughout the 7-day treatment period.
Actively Recruiting
Researchers are evaluating treatments for patients with psoriatic arthritis PsA who have not responded well to tumor necrosis factor inhibitors TNFi. The trial aims to find out if switching to guselkumab, a selective interleukin 23 inhibitor IL23i, is more effective than switching to a second TNFi, golimumab. This is the first study to compare these treatment switches in PsA patients and will focus on those who have an inadequate response to TNFi in a real-world clinical setting. Participants will be randomly assigned to one of three treatment groups guselkumab 100mg every 4 weeks, guselkumab 100mg every 8 weeks, or golimumab 50mg every 4 weeks. Both medications are given as subcutaneous injections. The study is open-label, meaning both patients and researchers know which treatment is given. The trial will continue for 12 months to assess treatment effectiveness. Throughout the study, participants will be monitored for disease activity using measures like cDAPSA low disease activity and Investigator Global Assessment of Psoriasis. Additional assessments include minimal disease activity, quality of life questionnaires, fatigue, and resolution of symptoms such as dactylitis and enthesitis. Safety and treatment response will be evaluated regularly, with the main outcomes measured at 6 and 12 months.
Actively Recruiting
Researchers are investigating treatment options for people with active rheumatoid arthritis RA who have not responded well to a tumor necrosis factor inhibitor TNFi biologic medication. The study compares two treatment strategies switching to a non-TNFi biologic drug such as rituximab, abatacept, tocilizumab, or sarilumab versus switching to a targeted synthetic disease-modifying antirheumatic drug tsDMARD like tofacitinib, baricitinib, or upadacitinib. This research addresses a significant gap in knowledge as current guidelines recommend switching treatments but lack strong evidence comparing these options directly, especially regarding patient-reported outcomes PROs like function and quality of life. Participants will be randomly assigned to receive either a non-TNFi biologic or a targeted synthetic DMARD. The choice of specific medication within each class is based on what is available and accessible through insurance or patient assistance programs. The study follows a pragmatic design to reflect real-world treatment decisions and includes patients with comorbidities. Treatment continues with stable doses of certain conventional synthetic DMARDs if already being used. This head-to-head trial aims to provide comparative effectiveness data for these two treatment strategies over a 12-month period. During the trial, participants will be monitored for changes in functional limitations using the Health Assessment Questionnaire HAQ, a sensitive tool for measuring outcomes important to patients with RA. Researchers will also track treatment toxicity and quality of life changes. The study involves regular assessments over one year to evaluate the benefits and risks of each treatment approach, helping patients and providers make informed decisions based on outcomes that matter most to patients.